Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 8/20 | 0.33 |
| ▸ | JAK2 | O60674 | 7/20 | 0.33 |
| ▸ | TYK2 | P29597 | 7/20 | 0.33 |
| ▸ | JAK3 | P52333 | 6/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714075 | 1.00 | VNN1 (0.35) | VNN1BRD4CHEK1CHEK2JAK1 | |
| SCHEMBL1714634 | 0.86 | BRD4 (0.36) | BRD4DYRK3DYRK1ADYRK2DYRK1B | |
| SCHEMBL1714637 | 0.86 | BRD4 (0.36) | BRD4DYRK3DYRK1ADYRK2DYRK1B | |
| SCHEMBL1714320 | 0.85 | CDC7 (0.33) | BRD4JAK2DYRK3CLK1CLK2 | |
| SCHEMBL1714321 | 0.85 | CDC7 (0.33) | BRD4JAK2DYRK3CLK1CLK2 | |
| SCHEMBL1714409 | 0.85 | PLK4 (0.33) | BRD4JAK2JAK3CLK2DYRK1A | |
| SCHEMBL1714215 | 0.85 | CRHR1 (0.33) | BRD4JAK2 | |
| SCHEMBL1714412 | 0.85 | PLK4 (0.33) | BRD4JAK2JAK3CLK2DYRK1A | |
| SCHEMBL1714219 | 0.85 | CRHR1 (0.33) | BRD4JAK2 | |
| SCHEMBL1713934 | 0.84 | MTNR1A (0.37) | CHEK1CHEK2JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | claimed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | claimed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| EP-2094699-B1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | VNN1 4502/4885BRD4 1806/4885CHEK1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.